<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC3184032/results/search/disease/results.xml">
  <result pre="drugs target 3 main groups of viruses: herpes, hepatitis, and" exact="influenza" post="viruses. With the exception of the antisense molecule fomivirsen,"/>
  <result pre="substrates for viral DNA polymerase. Drugs for the treatment of" exact="influenza" post="inhibit the ion channel M2 protein or the enzyme"/>
  <result pre="with Interferon-α and ribavirin remains the backbone treatment for chronic" exact="hepatitis" post="C; the addition of serine protease inhibitors improves the"/>
  <result pre="protease inhibitors improves the treatment outcome of patients infected with" exact="hepatitis" post="C virus genotype 1. Chronic hepatitis B can be"/>
  <result pre="of patients infected with hepatitis C virus genotype 1. Chronic" exact="hepatitis" post="B can be treated with interferon or a combination"/>
  <result pre="all the nucleos(t) ide analogues for the treatment of chronic" exact="hepatitis" post="B possess anti-human immunodeficiency virus properties, and they inhibit"/>
  <result pre="possess anti-human immunodeficiency virus properties, and they inhibit replication of" exact="hepatitis" post="B virus by serving as competitive substrates for its"/>
  <result pre="clinical applications, such as ribavirin for the treatment of chronic" exact="hepatitis" post="C and respiratory syncytial virus and cidofovir for the"/>
  <result pre="utility of M2 inhibitors for the prevention and treatment of" exact="influenza" post="infections. This article provides an overview of clinically available"/>
  <result pre="uses, and adverse effects. Abbreviations ALT, alanine aminotransferase CHB, chronic" exact="hepatitis" post="B CHC, chronic hepatitis C CMV, cytomegalovirus CSF, cerebrospinal"/>
  <result pre="Abbreviations ALT, alanine aminotransferase CHB, chronic hepatitis B CHC, chronic" exact="hepatitis" post="C CMV, cytomegalovirus CSF, cerebrospinal fluid EBV, Epstein-Barr virus"/>
  <result pre="EBV, Epstein-Barr virus FDA, US Food and Drug Administration HBeAg," exact="hepatitis" post="B e antigen HBV, hepatitis B virus HCV, hepatitis"/>
  <result pre="Food and Drug Administration HBeAg, hepatitis B e antigen HBV," exact="hepatitis" post="B virus HCV, hepatitis C virus HHV, human herpesvirus"/>
  <result pre="HBeAg, hepatitis B e antigen HBV, hepatitis B virus HCV," exact="hepatitis" post="C virus HHV, human herpesvirus HIV, human immunodeficiency virus"/>
  <result pre="C virus HHV, human herpesvirus HIV, human immunodeficiency virus HSV," exact="herpes simplex" post="virus HSV-1, HSV type 1 HSV-2, HSV type 2"/>
  <result pre="setting target 3 principal groups of viruses—the herpes, hepatitis, and" exact="influenza" post="viruses. This review article is structured to discuss antiviral"/>
  <result pre="DNA viral infections. Nucleos(t)ide analogues for the treatment of chronic" exact="hepatitis" post="B (CHB) may also possess anti-HIV properties, but their"/>
  <result pre="Acyclovir Acyclovir is a synthetic guanosine analogue used for treating" exact="herpes simplex" post="virus (HSV) and varicella zoster virus (VZV) infections.1, 2,"/>
  <result pre="is preferred for severe and disseminated disease Risk of crystalline" exact="nephropathy" post="Acyclovir (oral) 400 mg orally 3 times daily 800"/>
  <result pre="episode of genital herpes Recurrent episodes of genital herpes HSV" exact="encephalitis" post="Acyclovir (IV) 10 mg/kg IV every 8 h Risk"/>
  <result pre="(IV) 10 mg/kg IV every 8 h Risk of crystalline" exact="nephropathy" post="Long-term suppression Acyclovir (oral) 400 mg orally twice daily"/>
  <result pre="mg/kg IV every 8 h Risk of crystalline nephropathy Long-term" exact="suppression" post="Acyclovir (oral) 400 mg orally twice daily (400–800 mg"/>
  <result pre="every 12 h IVtherapy is preferred for severe CMV disease," exact="gastrointestinal disease," post="pneumonia, and encephalitis Transition to oral valganciclovir on clinical"/>
  <result pre="is preferred for severe CMV disease, gastrointestinal disease, pneumonia, and" exact="encephalitis" post="Transition to oral valganciclovir on clinical and virologic improvement"/>
  <result pre="should not be used for treating active CMV infection CMV" exact="retinitis" post="in HIV-infected patients Valganciclovir (oral) Induction: 900 mg orally"/>
  <result pre="requires concomitant hydration and probenecid use CMV disease other than" exact="retinitis" post="in HIV-infected patients Valganciclovir (oral) Induction: 900 mg orally"/>
  <result pre="acute retinal necrosis (which is associated with HSV or VZV)," exact="eczema herpeticum," post="and oral hairy leukoplakia due to EBV. Oral acyclovir"/>
  <result pre="is associated with HSV or VZV), eczema herpeticum, and oral" exact="hairy leukoplakia" post="due to EBV. Oral acyclovir is used to prevent"/>
  <result pre="associated with HSV or VZV), eczema herpeticum, and oral hairy" exact="leukoplakia" post="due to EBV. Oral acyclovir is used to prevent"/>
  <result pre="patients because of intratubular precipitation of acyclovir crystals. Acyclovir crystalline" exact="nephropathy" post="is more common when acyclovir is given as a"/>
  <result pre="It is available in some countries for the treatment of" exact="herpes zoster" post="and herpes simplex. However, concerns about its toxicity halted"/>
  <result pre="in some countries for the treatment of herpes zoster and" exact="herpes simplex." post="However, concerns about its toxicity halted its clinical development"/>
  <result pre="major clinical indication for cidofovir is the treatment of CMV" exact="retinitis" post="in HIV-infected patients (Table 1).31 Cidofovir is also used"/>
  <result pre="HSV disease, condyloma acuminatum, BK virus-associated hemorrhagic cystitis, JC virus-associated" exact="progressive multifocal leukoencephalopathy," post="and other infections due to double-stranded DNA viruses.34, 35,"/>
  <result pre="The major clinical indications for famciclovir use are treatment of" exact="herpes zoster," post="recurrent genital herpes,52 and recurrent herpes labialis.53 Famciclovir can"/>
  <result pre="and recurrent herpes labialis.53 Famciclovir can also be used as" exact="suppression" post="therapy to reduce the risk of recurrent genital herpes"/>
  <result pre="given intravitreally. Its main indication is the treatment of CMV" exact="retinitis" post="in patients with AIDS who have not benefited from"/>
  <result pre="is increased intraocular pressure and inflammation. Blurred vision, conjunctival hemorrhage," exact="retinal detachment," post="and retinal edema are other adverse effects.55, 56, 57"/>
  <result pre="pressure and inflammation. Blurred vision, conjunctival hemorrhage, retinal detachment, and" exact="retinal edema" post="are other adverse effects.55, 56, 57 Foscarnet Foscarnet is"/>
  <result pre="kinase mutations.33 Foscarnet is approved for the treatment of CMV" exact="retinitis" post="in patients with AIDS.58 It has been used to"/>
  <result pre="the glomerular capillary lumen.62, 63 Foscarnet may cause myelosuppression, with" exact="anemia" post="as the most common effect. It can chelate bivalent"/>
  <result pre="against HHV-7.67 Ganciclovir is approved for the treatment of CMV" exact="retinitis" post="in patients with AIDS, the treatment of herpes simplex"/>
  <result pre="of CMV retinitis in patients with AIDS, the treatment of" exact="herpes simplex" post="keratitis, and CMV prophylaxis in transplant recipients. Intravenous ganciclovir"/>
  <result pre="used to treat other forms of CMV disease, such as" exact="colitis" post="or esophagitis. Induction therapy with IV ganciclovir for CMV"/>
  <result pre="colitis or esophagitis. Induction therapy with IV ganciclovir for CMV" exact="retinitis" post="in patients with AIDS has an efficacy of 85%"/>
  <result pre="bone marrow and solid organ transplant recipients.61 Reversible bone marrow" exact="suppression" post="is the most common adverse effect of ganciclovir. Other"/>
  <result pre="the first dose should be started within 48 hours of" exact="rash" post="onset. Treatment can be prolonged, continuing until all lesions"/>
  <result pre="was first approved by the FDA for treatment of CMV" exact="retinitis" post="in patients with AIDS.83 For immediate sight-threatening lesions, valganciclovir"/>
  <result pre="moderate CMV disease in transplant recipients.86, 87, 89 Bone marrow" exact="suppression" post="is the most common adverse effect of valganciclovir. Gastrointestinal"/>
  <result pre="available only as an ophthalmic solution for treating recurrent epithelial" exact="keratitis" post="and acute keratoconjunctivitis.90 Once phosphorylated into its active form,"/>
  <result pre="Amantadine is a symmetric tricyclic amine that inhibits replication of" exact="influenza" post="A virus by impairing the function of the membrane"/>
  <result pre="the function of the membrane protein M2.91 Present only in" exact="influenza" post="A virus, M2 is an acid-activated ion channel required"/>
  <result pre="filtration and tubular secretion. Amantadine is effective for treating susceptible" exact="influenza" post="A virus infection.91 It results in a more rapid"/>
  <result pre="disease onset.91 Amantadine is effective as prophylaxis for preventing symptomatic" exact="influenza" post="A infection in exposed persons.92, 93 It is usually"/>
  <result pre="at least 7 days after the last confirmed illness. Seasonal" exact="influenza" post="vaccination, however, remains the preferred method for prevention. Amantadine"/>
  <result pre="rimantadine. Rimantadine. Rimantadine is a symmetric tricyclic amine that inhibits" exact="influenza" post="virus.93 It is well absorbed after oral administration, reaching"/>
  <result pre="viral uncoating. Rimantadine is indicated for prevention and treatment of" exact="influenza" post="A virus93; however, its clinical utility is currently limited"/>
  <result pre="inhibitor of neuraminidase that is essential in the replication of" exact="influenza" post="A and B viruses.98 Oral oseltamivir is well absorbed"/>
  <result pre="for the treatment of children (≥1 year) and adults with" exact="influenza" post="A or B viral infections.98 Treatment should start within"/>
  <result pre="inhibitor, zanamivir, in reducing the febrile period during infection with" exact="influenza" post="A (H1N1), influenza A (H3N2), and influenza B virus.99"/>
  <result pre="reducing the febrile period during infection with influenza A (H1N1)," exact="influenza" post="A (H3N2), and influenza B virus.99 Oseltamivir is also"/>
  <result pre="during infection with influenza A (H1N1), influenza A (H3N2), and" exact="influenza" post="B virus.99 Oseltamivir is also used for postexposure prophylaxis"/>
  <result pre="B virus.99 Oseltamivir is also used for postexposure prophylaxis against" exact="influenza" post="A and B, including pandemic strains. For this indication,"/>
  <result pre="significant difference between oseltamivir and zanamivir prophylaxis for preventing symptomatic" exact="influenza" post="among immunocompetent adults.100 The most common adverse effects of"/>
  <result pre="including delirium, abnormal behavior, and hallucinations, have been reported. Oseltamivir-resistant" exact="influenza" post="A virus has been reported.101, 102, 103 Mutations in"/>
  <result pre="account for oseltamivir resistance. Surveillance conducted during the 2009 H1N1" exact="influenza" post="pandemic detected sporadic and infrequent incidence of oseltamivir-resistant pandemic"/>
  <result pre="detected sporadic and infrequent incidence of oseltamivir-resistant pandemic (H1N1) 2009" exact="influenza" post="virus. All resistant viruses had neuraminidase mutations (most commonly"/>
  <result pre="resistance to oseltamivir, but not to zanamivir.104 Oseltamivir resistance among" exact="influenza" post="B viruses occurs less frequently.105 Zanamivir. Zanamivir is an"/>
  <result pre="inhibitor that is used for the treatment and prophylaxis of" exact="influenza" post="A and B viruses.106 Zanamivir is not available orally"/>
  <result pre="Inhaled zanamivir produces high concentrations in the respiratory tract where" exact="influenza" post="virus infection occurs. About 4% to 20% of inhaled"/>
  <result pre="given once daily for 10 days as postexposure prophylaxis of" exact="influenza" post="A and B in household or close contacts. Zanamivir"/>
  <result pre="to various cellular responses, such as inhibition of virus replication," exact="suppression" post="of cell proliferation, enhancement of the phagocytic activity of"/>
  <result pre="Interferon-α was the first drug approved for treatment of compensated" exact="liver disease" post="due to CHB; it is not approved for treating"/>
  <result pre="due to CHB; it is not approved for treating acute" exact="hepatitis" post="B. For CHB, IFN α-2a or α-2b is given"/>
  <result pre="113 Interferon was most effective in patients with recently acquired" exact="hepatitis" post="B virus (HBV), high pretreatment levels of alanine aminotransferase"/>
  <result pre="Likewise, SC peginterferon-α may be more effective than lamivudine in" exact="hepatitis" post="B e antigen (HBeAg)-positive and HBeAg-negative patients with CHB,115,"/>
  <result pre="enhance efficacy.118 Interferon-α is effective in patients with HBV and" exact="hepatitis" post="D virus confection,119 although they are less responsive than"/>
  <result pre="Interferon-α-2a and -2b are approved for the treatment of chronic" exact="hepatitis" post="C (CHC); however, they are not approved for acute"/>
  <result pre="hepatitis C (CHC); however, they are not approved for acute" exact="hepatitis" post="C. A meta-analysis found that IFN-α for at least"/>
  <result pre="in patients not infected with HIV is 24 weeks (for" exact="hepatitis" post="C virus [HCV] genotype 2 or 3) or 48"/>
  <result pre="for 48 weeks. Interferons are generally not recommended in acute" exact="viral hepatitis," post="but treatment of acute HCV with IFN-α has resulted"/>
  <result pre="disturbances (eg, confusion and seizures), myelosuppression (neutropenia [most commonly] and" exact="aplastic anemia" post="[rarely]), cardiovascular disorders (eg, arrhythmias), endocrine disorders (eg, thyroid"/>
  <result pre="(eg, confusion and seizures), myelosuppression (neutropenia [most commonly] and aplastic" exact="anemia" post="[rarely]), cardiovascular disorders (eg, arrhythmias), endocrine disorders (eg, thyroid"/>
  <result pre="triphosphate, is a potent competitive inhibitor of inosine monophosphate dehydrogenase," exact="influenza" post="virus RNA polymerase, and mRNA guanylyltransferase. As a result"/>
  <result pre="has been used, off-label, for the treatment of HSV, influenza," exact="severe acute respiratory syndrome" post="coronavirus,154, 155 La Crosse encephalitis,156 Nipah encephalitis,157 Lassa fever,158"/>
  <result pre="Precipitation of inhaled ribavirin may occur in ventilatory tubings. Hemolytic" exact="anemia" post="occurs commonly,154 and ribavirin should not be given to"/>
  <result pre="relapse often occurs after discontinuation of treatment. Severe exacerbation of" exact="hepatitis" post="may also occur on discontinuation of these drugs; hence,"/>
  <result pre="Acyclic nucleotide analogue of adenosine monophosphate Nephrotoxicity Lactic acidosis Rebound" exact="hepatitis" post="rtN236T is most common Emtricitabine 200 mg orally once"/>
  <result pre="lamivudine Used often in combination with tenofovir Lactic acidosis Rebound" exact="hepatitis" post="rtM204V/I provides cross-resistance with lamivudine Entecavir 0.5 mg orally"/>
  <result pre="orally once daily for treatment-experienced patients and patients with decompensated" exact="liver disease" post="Nucleoside analogue of guanosine One of the most potent"/>
  <result pre="the most potent anti-HBV drugs Well tolerated Lactic acidosis Rebound" exact="hepatitis" post="High barrier to resistance; requires 3 mutations for phenotype:"/>
  <result pre="once daily Nucleoside analogue of cytosine Lactic acidosis Myopathy Rebound" exact="hepatitis" post="rtM204V/I is most frequent Telbivudine 600 mg orally once"/>
  <result pre="Synthetic thymidine nucleoside analogue No activity against HIV Myopathy Peripheral" exact="neuropathy" post="Lactic acidosis Rebound hepatitis rtM204I is most frequent mutation;"/>
  <result pre="No activity against HIV Myopathy Peripheral neuropathy Lactic acidosis Rebound" exact="hepatitis" post="rtM204I is most frequent mutation; others include rtL80I/V, rtA181T,"/>
  <result pre="of the most potent anti-HBV drugs Nephrotoxicity Lactic acidosis Rebound" exact="hepatitis" post="Not well-defined; rtN236T is suggested but not yet confirmed"/>
  <result pre="well-defined; rtN236T is suggested but not yet confirmed aHBV =" exact="hepatitis" post="B virus; HIV = human immunodeficiency virus. bAll drugs"/>
  <result pre="B virus; HIV = human immunodeficiency virus. bAll drugs inhibit" exact="hepatitis" post="B replication by acting as a competitive substrate for"/>
  <result pre="except telbivudine have anti-HBV properties, and all patients with chronic" exact="hepatitis" post="B who are considered for treatment should be screened"/>
  <result pre="for HIV. cA common toxicity of the nucleos(t)ide analogues is" exact="lactic acidosis," post="with the potential to cause increases in serum alaninę"/>
  <result pre="anti-HBV drugs, it has been used in adults with decompensated" exact="liver disease," post="or with compensated liver disease with evidence of active"/>
  <result pre="used in adults with decompensated liver disease, or with compensated" exact="liver disease" post="with evidence of active viral replication, persistently elevated ALT"/>
  <result pre="approved for the treatment of CHB in patients with compensated" exact="liver disease" post="and evidence of active viral replication, persistently increased serum"/>
  <result pre="dizziness, fatigue, gastrointestinal symptoms, and rash. Unique adverse effects are" exact="peripheral neuropathy" post="and myopathy with elevation in creatine kinase levels. Telbivudine"/>
  <result pre="fatigue, gastrointestinal symptoms, and rash. Unique adverse effects are peripheral" exact="neuropathy" post="and myopathy with elevation in creatine kinase levels. Telbivudine"/>
  <result pre="symptoms, and rash. Unique adverse effects are peripheral neuropathy and" exact="myopathy" post="with elevation in creatine kinase levels. Telbivudine treatment should"/>
  <result pre="creatine kinase levels. Telbivudine treatment should be discontinued if either" exact="peripheral neuropathy" post="or myopathy is diagnosed. The rate of resistance to"/>
  <result pre="kinase levels. Telbivudine treatment should be discontinued if either peripheral" exact="neuropathy" post="or myopathy is diagnosed. The rate of resistance to"/>
  <result pre="Telbivudine treatment should be discontinued if either peripheral neuropathy or" exact="myopathy" post="is diagnosed. The rate of resistance to telbivudine is"/>
  <result pre="anemia.194 The addition of boceprevir nearly doubled the rate of" exact="anemia" post="compared with the use of standard peginterferon and ribavirin"/>
  <result pre="can be mild to severe, and Stevens-Johnson syndrome and drug" exact="rash" post="with eosinophilia and systemic symptoms have been reported. Telaprevir"/>
  <result pre="mild to severe, and Stevens-Johnson syndrome and drug rash with" exact="eosinophilia" post="and systemic symptoms have been reported. Telaprevir therapy should"/>
  <result pre="if these dermatologic complications occur, especially in cases of severe" exact="rash" post="or even mild to moderate rash if accompanied by"/>
  <result pre="in cases of severe rash or even mild to moderate" exact="rash" post="if accompanied by systemic symptoms. The mechanism underlying rash"/>
  <result pre="moderate rash if accompanied by systemic symptoms. The mechanism underlying" exact="rash" post="development is unknown.199 Fatigue, pruritus, and gastrointestinal sympotoms (eg,"/>
  <result pre="drugs target 3 main groups of viruses: herpes, hepatitis, and" exact="influenza" post="viruses. The antiviral therapeutic armamentarium has evolved over the"/>
  <result pre="their clinical utility for most infections, such as acyclovir for" exact="herpes simplex" post="virus and ganciclovir for CMV. However, other of these"/>
  <result pre="of these &quot;old&quot; antiviral drugs (eg, amantadine and rimantadine for" exact="influenza" post="virus infections) have lost their clinical utility because of"/>
  <result pre="been observed to the neuraminidase inhibitors for the treatment of" exact="influenza" post="viruses and the nucleos(t)ide analogues for the treatment of"/>
  <result pre="treatment of initial and recurrent genital herpesLancet219825715736125728 3SerotaFTStarrSEBryanCKKochPAPlotkinSAAugustCSAcyclovir treatment of" exact="herpes zoster" post="infections: use in children undergoing bone marrow transplantationJAMA2471982213221357038177 4GuptaRWarrenTWaldAGenital"/>
  <result pre="undergoing bone marrow transplantationJAMA2471982213221357038177 4GuptaRWarrenTWaldAGenital herpesLancet37020072127213718156035 5ReichmanRCBadgerGJMertzGJTreatment of recurrent genital" exact="herpes simplex" post="infections with oral acyclovir: a controlled trialJAMA2511984210321076368877 6LubyJPGnannJWJrAlexanderWJA collaborative"/>
  <result pre="with topical acyclovir or placeboJ Infect Dis1501984166086765 7CernikCGallinaKBrodellRTThe treatment of" exact="herpes simplex" post="infections: an evidence-based reviewArch Intern Med16820081137114418541820 8ZuckermanRWaldAHerpes simplex virus"/>
  <result pre="treatment of herpesvirus infectionsJ Antimicrob Chemother32suppl A19931211328407694 10ValenciaIMilesDKMelvinJRelapse of herpes" exact="encephalitis" post="after acyclovir therapy: report of two new cases and"/>
  <result pre="administrationAnn Pharmacother271993145814598305776 21AmosRJAmessJAMegaloblastic haemopoiesis due to acyclovirLancet11983242243 22Danve-SzatanekCAymardMThouvenotDSurveillance network for" exact="herpes simplex" post="virus resistance to antiviral drugs: 3-year follow-upJ Clin Microbiol42200424224914715760"/>
  <result pre="Microbiol Rev16200311412812525428 24MalvyDTreilhaudMBoueeSA retrospective, case-control study of acyclovir resistance in" exact="herpes simplex" post="virusClin Infect Dis41200532032616007528 25SupertiFAmmendoliaMGMarchettiMNew advances in anti-HSV chemotherapyCurr Med"/>
  <result pre="diseaseAnn Pharmacother321998118111929825085 32CherringtonJMFullerMDLamyPDIn vitro antiviral susceptibilities of isolates from cytomegalovirus" exact="retinitis" post="patients receiving first- or second-line cidofovir therapy: relationship to"/>
  <result pre="for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia," exact="herpes simplex" post="and its potential use in smallpoxDermatol Clin21200330130912757253 38LalezariJPDrewWLGlutzerETreatment with"/>
  <result pre="Clin21200330130912757253 38LalezariJPDrewWLGlutzerETreatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with" exact="herpes simplex" post="virus in a patient with AIDSJ Infect Dis17019945705728077713 39BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful"/>
  <result pre="a patient with AIDSJ Infect Dis17019945705728077713 39BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful treatment of foscarnet-resistant" exact="herpes simplex" post="stomatitis with intravenous cidofovir in a childPediatr Infect Dis"/>
  <result pre="with AIDSJ Infect Dis17019945705728077713 39BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful treatment of foscarnet-resistant herpes simplex" exact="stomatitis" post="with intravenous cidofovir in a childPediatr Infect Dis J2020011083108611734717"/>
  <result pre="a childPediatr Infect Dis J2020011083108611734717 40KoppTGeusauARiegerAStinglGSuccessful treatment of an aciclovir-resistant" exact="herpes simplex" post="type 2 infection with cidofovir in an AIDS patientBr"/>
  <result pre="cidofovir: a case seriesAIDS20200679179316514320 42MarraCMRajicicNBarkerDEA pilot study of cidofovir for" exact="progressive multifocal leukoencephalopathy" post="in AIDSAIDS1620021791179712218391 43RazonableRRAksamitAJWrightAJWilsonJWCidofovir treatment of progressive multifocal leukoencephalopathy in"/>
  <result pre="cidofovir for progressive multifocal leukoencephalopathy in AIDSAIDS1620021791179712218391 43RazonableRRAksamitAJWrightAJWilsonJWCidofovir treatment of" exact="progressive multifocal leukoencephalopathy" post="in a patient receiving highly active antiretroviral therapyMayo Clin"/>
  <result pre="44Segarra-NewnhamMVodoloKMUse of cidofovir in progressive multifocal leukoencephalopathyAnn Pharmacother35200174174411408993 45ViallardJFLazaroEEllieEImprovement of" exact="progressive multifocal leukoencephalopathy" post="after cidofovir therapy in a patient with a destructive"/>
  <result pre="and acute renal failure associated with cidofovirJ Antimicrob Chemother60200719319417496056 49AmbatiJWynneKBAngerameMCRobinsonMRAnterior" exact="uveitis" post="associated with intravenous cidofovir use in patients with cytomegalovirus"/>
  <result pre="new single-day dosing indicationsCutis802007778117725069 54SaltzmanRJurewiczRBoonRSafety of famciclovir in patients with" exact="herpes zoster" post="and genital herpesAntimicrob Agents Chemother381994245424577840587 55GrilloneLRLanzRFomivirsenDrugs Today (Barc)37200124525512768225 56Vitravene"/>
  <result pre="of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus" exact="retinitis" post="in patients with AIDSAm J Ophthalmol133200246747411931780 57HighleymanLFomivirsenBETA29199831 58ChrispPClissoldSPFoscarnet: a"/>
  <result pre="dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus" exact="retinitis" post="in AIDSJ Infect Dis16819934444488393058 63BeaufilsHDerayGKatlamaCFoscarnet and crystals in glomerular"/>
  <result pre="therapy and prevention of CMV infectionsJ Clin Virol162000254010680738 66FrankKBChiouJFChengYCInteraction of" exact="herpes simplex" post="virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphateJ Biol Chem2591984156615696319402 67RazonableRRPayaCVThe"/>
  <result pre="randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral" exact="retinitis" post="in patients with AIDSJ Infect Dis16819935575638394858 69DrewWLIvesDLalezariJPSyntex Cooperative Oral"/>
  <result pre="Oral Ganciclovir Study GroupOral ganciclovir as maintenance treatment for cytomegalovirus" exact="retinitis" post="in patients with AIDSN Engl J Med33319956156207637721 70GaneESalibaFValdecasasGJOral Ganciclovir"/>
  <result pre="outcomesClin Transplant22200816217018339135 72SariskyRTBaconTHBoonRJProfiling penciclovir susceptibility and prevalence of resistance of" exact="herpes simplex" post="virus isolates across eleven clinical trialsArch Virol14820031757176914505088 73BaconTHBoydMRActivity of"/>
  <result pre="74SpruanceSLReaTLThomingCTuckerRSaltzmanRBoonRTopical Penciclovir Collaborative Study GroupPenciclovir cream for the treatment of" exact="herpes simplex" post="labialis: a randomized, multicenter, double-blind, placebo-controlled trialJAMA2771997137413799134943 75AcostaEPFletcherCVValacyclovirAnn Pharmacother3119971851919034421"/>
  <result pre="in solid organ transplant recipientsAm J Transplant720072106211317640310 90WilhelmusKRTherapeutic interventions for" exact="herpes simplex" post="virus epithelial keratitisCochrane Database Syst Rev2008CD00289818254009 91De ClercqEAntiviral drugs"/>
  <result pre="Clin Virol30200411513315125867 92TappendenPJacksonRCooperKAmantadine, oseltamivir and zanamivir for the prophylaxis of" exact="influenza" post="(including a review of existing guidance no. 67): a"/>
  <result pre="Technol Assess131120091246iii, ix-xii 93BettsRFAmantadine and rimantadine for the prevention of" exact="influenza" post="ASemin Respir Infect419893043102697053 94KrumbholzASchmidtkeMBergmannSHigh prevalence of amantadine resistance among"/>
  <result pre="Infect419893043102697053 94KrumbholzASchmidtkeMBergmannSHigh prevalence of amantadine resistance among circulating European porcine" exact="influenza" post="A virusesJ Gen Virol90200990090819223487 95HigginsRREshaghiABurtonLMazzulliTDrewsSJDifferential patterns of amantadine-resistance in"/>
  <result pre="influenza A virusesJ Gen Virol90200990090819223487 95HigginsRREshaghiABurtonLMazzulliTDrewsSJDifferential patterns of amantadine-resistance in" exact="influenza" post="A (H3N2) and (H1N1) isolates in Toronto, CanadaJ Clin"/>
  <result pre="isolates in Toronto, CanadaJ Clin Virol442009919319019729 96HaydenFGHayAJEmergence and transmission of" exact="influenza" post="A viruses resistant to amantadine and rimantadineCurr Top Microbiol"/>
  <result pre="to amantadine and rimantadineCurr Top Microbiol Immunol17619921191301600749 97HaydenFGSperberSJBelsheRBCloverRDHayAJPykeSRecovery of drug-resistant" exact="influenza" post="A virus during therapeutic use of rimantadineAntimicrob Agents Chemother351991174117471952841"/>
  <result pre="and its potential for use in the event of an" exact="influenza" post="pandemicJ Antimicrob Chemother55suppl 12005i5i2115709056 99SugayaNTamuraDYamazakiMComparison of the clinical effectiveness"/>
  <result pre="99SugayaNTamuraDYamazakiMComparison of the clinical effectiveness of oseltamivir and zanamivir against" exact="influenza" post="virus infection in childrenClin Infect Dis47200833934518582202 100KhazeniNBravataDMHoltyJEUyekiTMStaveCDGouldMKSystematic review: safety"/>
  <result pre="antiviral chemoprophylaxis against pandemic and seasonal influenzaAnn Intern Med151200946447319652173 101KisoMMitamuraKSakai-TagawaYResistant" exact="influenza" post="A viruses in children treated with oseltamivir: descriptive studyLancet364200475976515337401"/>
  <result pre="with oseltamivir: descriptive studyLancet364200475976515337401 102de JongMDTranTTTruongHKOseltamivir resistance during treatment of" exact="influenza" post="A (H5N1) infectionN Engl J Med35320052667267216371632 103LeQMKisoMSomeyaKAvian flu: isolation"/>
  <result pre="103LeQMKisoMSomeyaKAvian flu: isolation of drug-resistant H5N1 virusNature4372005110816228009 104DharanNJGubarevaLVMeyerJJInfections with oseltamivir-resistant" exact="influenza" post="A(H1N1) virus in the United StatesJAMA30120091034104119255110 105HatakeyamaSSugayaNItoMEmergence of influenza"/>
  <result pre="oseltamivir-resistant influenza A(H1N1) virus in the United StatesJAMA30120091034104119255110 105HatakeyamaSSugayaNItoMEmergence of" exact="influenza" post="B viruses with reduced sensitivity to neuraminidase inhibitorsJAMA29720071435144217405969 106FreundBGravensteinSElliottMMillerIZanamivir:"/>
  <result pre="of clinical safetyDrug Saf21199926728110514019 107GaurAHBaggaBBarmanSIntravenous zanamivir for oseltamivir-resistant 2009 H1N1" exact="influenza" post="[letter]N Engl J Med36212010888920032317 108KiddIMDownJNastouliEH1N1 pneumonitis treated with intravenous"/>
  <result pre="Liver Dis23suppl 12003192212934164 112WongDKCheungAMO'RourkeKNaylorCDDetskyASHeathcoteJEffect of alpha-interferon treatment in patients with" exact="hepatitis" post="B e antigen-positive chronic hepatitis B: a meta-analysisAnn Intern"/>
  <result pre="alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic" exact="hepatitis" post="B: a meta-analysisAnn Intern Med11919933123238328741 113HariaMBenfieldPInterferon-alpha-2a: a review of"/>
  <result pre="and therapeutic use in the management of viral hepatitisDrugs5019958738968586031 114LokASMcMahonBJChronic" exact="hepatitis" post="B: update 2009Hepatology50200966166219714720 115MarcellinPAsselahTBoyerNTreatment of chronic hepatitis BJ Viral"/>
  <result pre="viral hepatitisDrugs5019958738968586031 114LokASMcMahonBJChronic hepatitis B: update 2009Hepatology50200966166219714720 115MarcellinPAsselahTBoyerNTreatment of chronic" exact="hepatitis" post="BJ Viral Hepat12200533334515985003 116LauGKPiratvisuthTLuoKXPeginterferon alfa-2a, lamivudine, and the combination"/>
  <result pre="Hepat12200533334515985003 116LauGKPiratvisuthTLuoKXPeginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic" exact="hepatitis" post="BN Engl J Med35220052682269515987917 117MarcellinPLauGKBoninoFPeginterferon alfa-2a alone, lamivudine alone,"/>
  <result pre="and the two in combination in patients with HBeAg-negative chronic" exact="hepatitis" post="BN Engl J Med35120041206121715371578 118JanssenHLvan ZonneveldMSenturkHPegylated Interferon alfa-2b alone"/>
  <result pre="alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic" exact="hepatitis" post="B: a randomised trialLancet365200512312915639293 119FarciPMandasACoianaATreatment of chronic hepatitis D"/>
  <result pre="HBeAg-positive chronic hepatitis B: a randomised trialLancet365200512312915639293 119FarciPMandasACoianaATreatment of chronic" exact="hepatitis" post="D with interferon alfa-2aN Engl J Med330199488948259188 120FarciPRoskamsTChessaLLong-term benefit"/>
  <result pre="J Med330199488948259188 120FarciPRoskamsTChessaLLong-term benefit of interferon alpha therapy of chronic" exact="hepatitis" post="D: regression of advanced hepatic fibrosisGastroenterology12620041740174915188169 121SorianoVPuotiMBonaciniMCare of patients"/>
  <result pre="regression of advanced hepatic fibrosisGastroenterology12620041740174915188169 121SorianoVPuotiMBonaciniMCare of patients with chronic" exact="hepatitis" post="B and HIV co-infection: recommendations from an HIV-HBV International"/>
  <result pre="the first European Consensus Conference on the treatment of chronic" exact="hepatitis" post="B and C in HIV co-infected patientsJ Hepatol42200561562415916745 123PoynardTLeroyVCohardMMeta-analysis"/>
  <result pre="Hepatol42200561562415916745 123PoynardTLeroyVCohardMMeta-analysis of interferon randomized trials in the treatment of" exact="viral hepatitis" post="C: effects of dose and durationHepatology2419967787898855176 124ZeuzemSFeinmanSVRasenackJPeginterferon alfa-2a in"/>
  <result pre="123PoynardTLeroyVCohardMMeta-analysis of interferon randomized trials in the treatment of viral" exact="hepatitis" post="C: effects of dose and durationHepatology2419967787898855176 124ZeuzemSFeinmanSVRasenackJPeginterferon alfa-2a in"/>
  <result pre="of dose and durationHepatology2419967787898855176 124ZeuzemSFeinmanSVRasenackJPeginterferon alfa-2a in patients with chronic" exact="hepatitis" post="CN Engl J Med34320001666167211106715 125PerryCMJarvisBPeginterferon-alpha-2a (40 kD): a review"/>
  <result pre="a review of its use in the management of chronic" exact="hepatitis" post="CDrugs6120012263228811772139 126HeathcoteEJShiffmanMLCooksleyWGPeginterferon alfa-2a in patients with chronic hepatitis C"/>
  <result pre="of chronic hepatitis CDrugs6120012263228811772139 126HeathcoteEJShiffmanMLCooksleyWGPeginterferon alfa-2a in patients with chronic" exact="hepatitis" post="C and cirrhosisN Engl J Med34320001673168011106716 127BrokJGluudLLGluudCRibavirin plus interferon"/>
  <result pre="Engl J Med34320001673168011106716 127BrokJGluudLLGluudCRibavirin plus interferon versus interferon for chronic" exact="hepatitis" post="CCochrane Database Syst Rev12010CD00544520091577 128FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for"/>
  <result pre="CCochrane Database Syst Rev12010CD00544520091577 128FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C virus infectionN Engl J Med347200297598212324553 129MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus"/>
  <result pre="with interferon alfa-2b plus ribavirin for initial treatment of chronic" exact="hepatitis" post="C: a randomised trialLancet358200195896511583749 130GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and treatment of"/>
  <result pre="hepatitis C: a randomised trialLancet358200195896511583749 130GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and treatment of" exact="hepatitis" post="C: an updateHepatology4920091335137419330875 131CarratFBani-SadrFPolSPegylated interferon alfa-2b vs standard interferon"/>
  <result pre="interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic" exact="hepatitis" post="C in HIV-infected patients: a randomized controlled trialJAMA29220042839284815598915 132TorrianiFJRodriguez-TorresMRockstrohJKPeginterferon"/>
  <result pre="a randomized controlled trialJAMA29220042839284815598915 132TorrianiFJRodriguez-TorresMRockstrohJKPeginterferon Alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C virus infection in HIV-infected patientsN Engl J Med351200443845015282351"/>
  <result pre="Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C in HIV-coinfected personsN Engl J Med351200445145915282352 134JaeckelECornbergMWedemeyerHTreatment of"/>
  <result pre="C in HIV-coinfected personsN Engl J Med351200445145915282352 134JaeckelECornbergMWedemeyerHTreatment of acute" exact="hepatitis" post="C with interferon alfa-2bN Engl J Med34520011452145711794193 135SantantonioTFasanoMSinisiEEfficacy of"/>
  <result pre="24-week course of PEG-interferon alpha-2b monotherapy in patients with acute" exact="hepatitis" post="C after failure of spontaneous clearanceJ Hepatol42200532933315710214 136EronLJJudsonFTuckerSInterferon therapy"/>
  <result pre="the treatment of genital herpesDrugs6020001329135211152015 138HuangSSSkolaskyRLDal PanGJRoyalWIIIMcArthurJCSurvival prolongation in HIV-associated" exact="progressive multifocal leukoencephalopathy" post="treated with alpha-interferon: an observational studyJ Neurovirol419983243329639075 139GeschwindMDSkolaskyRIRoyalWSMcArthurJCThe relative"/>
  <result pre="139GeschwindMDSkolaskyRIRoyalWSMcArthurJCThe relative contributions of HAART and alpha-interferon for therapy of" exact="progressive multifocal leukoencephalopathy" post="in AIDSJ Neurovirol7200135335711517416 140RenaultPFHoofnagleJHParkYPsychiatric complications of long-term interferon alfa"/>
  <result pre="long-term interferon alfa therapyArch Intern Med1471987157715803307672 141DieperinkEWillenbringMHoSBNeuropsychiatric symptoms associated with" exact="hepatitis" post="C and interferon19 alpha: a reviewAm J Psychiatry157200086787610831463 142MidturiJSierra-HoffmanMHurleyDWinnRBeissnerRCarpenterJSpectrum"/>
  <result pre="pulmonary toxicity associated with the use of interferon therapy for" exact="hepatitis" post="C: case report and review of the literatureClin Infect"/>
  <result pre="J Med344200196196611274622 145DurandJMKaplanskiGPortalIScheinerCBerlandYSoubeyrandJLiver failure due to recombinant alpha interferonLancet338199112681269 146AverbuchSDAustinHAIIISherwinSAAntonovychTBunnPAJrLongoDLAcute" exact="interstitial nephritis" post="with the nephrotic syndrome following recombinant leukocyte a interferon"/>
  <result pre="Med344200196196611274622 145DurandJMKaplanskiGPortalIScheinerCBerlandYSoubeyrandJLiver failure due to recombinant alpha interferonLancet338199112681269 146AverbuchSDAustinHAIIISherwinSAAntonovychTBunnPAJrLongoDLAcute interstitial" exact="nephritis" post="with the nephrotic syndrome following recombinant leukocyte a interferon"/>
  <result pre="due to recombinant alpha interferonLancet338199112681269 146AverbuchSDAustinHAIIISherwinSAAntonovychTBunnPAJrLongoDLAcute interstitial nephritis with the" exact="nephrotic syndrome" post="following recombinant leukocyte a interferon therapy for mycosis fungoidesN"/>
  <result pre="the nephrotic syndrome following recombinant leukocyte a interferon therapy for" exact="mycosis" post="fungoidesN Engl J Med310198432356689738 147AgestaNZabalaRDiaz-PerezJLAlopecia areata during interferon alpha-2b/ribavirin"/>
  <result pre="during interferon alpha-2b/ribavirin therapyDermatology205200230030112399683 148WadeJRSnoeckEDuffFLambMJorgaKPharmacokinetics of ribavirin in patients with" exact="hepatitis" post="C virusBr J Clin Pharmacol62200671071417118126 149KramerTHGaarGGRayCGMinnichLCopelandJGConnorJDHemodialysis clearance of intravenously"/>
  <result pre="and ribavirin-like moleculesJ Antimicrob Chemother57200681316293677 151GluudLLMarchesiniEIorioAPeginterferon plus ribavirin for chronic" exact="hepatitis" post="C in patients with human immunodeficiency virusAm J Gastroenterol10420092335234119513022"/>
  <result pre="154KnowlesSRPhillipsEJDresserLMatukasLCommon adverse events associated with the use of ribavirin for" exact="severe acute respiratory syndrome" post="in CanadaClin Infect Dis3720031139114214523782 155MullerMPDresserLRaboudJAdverse events associated with high-dose"/>
  <result pre="acute respiratory syndromePharmacotherapy27200749450317381375 156McJunkinJEKhanRde los ReyesECTreatment of severe La Crosse" exact="encephalitis" post="with intravenous ribavirin following diagnosis by brain biopsyPediatrics9919972612679024460 157ChongHTKamarulzamanATanCTTreatment"/>
  <result pre="ribavirin following diagnosis by brain biopsyPediatrics9919972612679024460 157ChongHTKamarulzamanATanCTTreatment of acute Nipah" exact="encephalitis" post="with ribavirinAnn Neurol49200181081311409437 158McCormickJBKingIJWebbPALassa fever: effective therapy with ribavirinN"/>
  <result pre="Med329199317448232482 164DandoTPloskerGAdefovir dipivoxil: a review of its use in chronic" exact="hepatitis" post="BDrugs6320032215223414498759 165RivkinAMAdefovir dipivoxil in the treatment of chronic hepatitis"/>
  <result pre="chronic hepatitis BDrugs6320032215223414498759 165RivkinAMAdefovir dipivoxil in the treatment of chronic" exact="hepatitis" post="BAnn Pharmacother38200462563314990784 166MarcellinPChangTTLimSGAdefovir dipivoxil for the treatment of hepatitis"/>
  <result pre="chronic hepatitis BAnn Pharmacother38200462563314990784 166MarcellinPChangTTLimSGAdefovir dipivoxil for the treatment of" exact="hepatitis" post="B e antigen-positive chronic hepatitis BN Engl J Med348200380881612606735"/>
  <result pre="dipivoxil for the treatment of hepatitis B e antigen-positive chronic" exact="hepatitis" post="BN Engl J Med348200380881612606735 167HadziyannisSJTassopoulosNCHeathcoteEJAdefovir dipivoxil for the treatment"/>
  <result pre="BN Engl J Med348200380881612606735 167HadziyannisSJTassopoulosNCHeathcoteEJAdefovir dipivoxil for the treatment of" exact="hepatitis" post="B e antigen-negative chronic hepatitis BN Engl J Med348200380080712606734"/>
  <result pre="dipivoxil for the treatment of hepatitis B e antigen-negative chronic" exact="hepatitis" post="BN Engl J Med348200380080712606734 168HadziyannisSJTassopoulosNCHeathcoteEJLong-term therapy with adefovir dipivoxil"/>
  <result pre="J Med348200380080712606734 168HadziyannisSJTassopoulosNCHeathcoteEJLong-term therapy with adefovir dipivoxil for HBeAg-negative chronic" exact="hepatitis" post="BN Engl J Med35220052673268115987916 169DelaneyWEProgress in the treatment of"/>
  <result pre="BN Engl J Med35220052673268115987916 169DelaneyWEProgress in the treatment of chronic" exact="hepatitis" post="B: long-term experience with adefovir dipivoxilJ Antimicrob Chemother59200782783217332007 170LimSGNgTMKungNA"/>
  <result pre="Antimicrob Chemother59200782783217332007 170LimSGNgTMKungNA double-blind placebo-controlled study of emtricitabine in chronic" exact="hepatitis" post="BArch Intern Med1662006495616401810 171SimsKAWoodlandAMEntecavir: a new nucleoside analog for"/>
  <result pre="171SimsKAWoodlandAMEntecavir: a new nucleoside analog for the treatment of chronic" exact="hepatitis" post="B infectionPharmacotherapy2620061745175717125436 172MatthewsSJEntecavir for the treatment of chronic hepatitis"/>
  <result pre="chronic hepatitis B infectionPharmacotherapy2620061745175717125436 172MatthewsSJEntecavir for the treatment of chronic" exact="hepatitis" post="B virus infectionClin Ther28200618420316678641 173ScottLJKeatingGMEntecavir: a review of its"/>
  <result pre="infectionClin Ther28200618420316678641 173ScottLJKeatingGMEntecavir: a review of its use in chronic" exact="hepatitis" post="BDrugs6920091003103319496629 174JohnsonMAMooreKHYuenGJByeAPakesGEClinical pharmacokinetics of lamivudineClin Pharmacokinet3619994166 175DienstagJLPerrilloRPSchiffERBartholomewMVicaryCRubinMA preliminary trial"/>
  <result pre="of lamivudineClin Pharmacokinet3619994166 175DienstagJLPerrilloRPSchiffERBartholomewMVicaryCRubinMA preliminary trial of lamivudine for chronic" exact="hepatitis" post="B infectionN Engl J Med3331995165716617477217 176DienstagJLSchiffERWrightTLLamivudine as initial treatment"/>
  <result pre="infectionN Engl J Med3331995165716617477217 176DienstagJLSchiffERWrightTLLamivudine as initial treatment for chronic" exact="hepatitis" post="B in the United StatesN Engl J Med34119991256126310528035 177LaiCLChienRNLeungNWAsia"/>
  <result pre="Hepatitis Lamivudine Study GroupA one-year trial of lamivudine for chronic" exact="hepatitis" post="BN Engl J Med339199861689654535 178HonkoopPde ManRAHeijtinkRASchalmSWHepatitis B reactivation after"/>
  <result pre="impairmentJ Clin Pharmacol49200972573419395586 180KimJWParkSHLouieSGTelbivudine: a novel nucleoside analog for chronic" exact="hepatitis" post="BAnn Pharmacother40200647247816507625 181JonesRNelsonMNovel anti-hepatitis B agents: a focus on"/>
  <result pre="J Clin Pract6020061295129916981973 182LaiCLGaneELiawYFTelbivudine versus lamivudine in patients with chronic" exact="hepatitis" post="BN Engl J Med35720072576258818094378 183ChanHLHeathcoteEJMarcellinPTreatment of hepatitis B e"/>
  <result pre="patients with chronic hepatitis BN Engl J Med35720072576258818094378 183ChanHLHeathcoteEJMarcellinPTreatment of" exact="hepatitis" post="B e antigen positive chronic hepatitis with telbivudine or"/>
  <result pre="J Med35720072576258818094378 183ChanHLHeathcoteEJMarcellinPTreatment of hepatitis B e antigen positive chronic" exact="hepatitis" post="with telbivudine or adefovir: a randomized trialAnn Intern Med147200774575417909201"/>
  <result pre="186GallantJEDeresinskiSTenofovir disoproxil fumarateClin Infect Dis37200394495013130407 187WongSNLokASTenofovir disoproxil fumarate: role in" exact="hepatitis" post="B treatmentHepatology44200630931316871562 188ReijndersJGJanssenHLPotency of tenofovir in chronic hepatitis B:"/>
  <result pre="role in hepatitis B treatmentHepatology44200630931316871562 188ReijndersJGJanssenHLPotency of tenofovir in chronic" exact="hepatitis" post="B: mono or combination therapy?J Hepatol48200838338618191272 189GitmanMDHirschwerkDBaskinCHSinghalPCTenofovir-induced kidney injuryExpert"/>
  <result pre="the FDA adverse event reporting systemAIDS Patient Care STDS2220089910318260800 191SchmidSOpravilMModdelMAcute" exact="interstitial nephritis" post="of HIV-positive patients under atazanavir and tenofovir therapy in"/>
  <result pre="FDA adverse event reporting systemAIDS Patient Care STDS2220089910318260800 191SchmidSOpravilMModdelMAcute interstitial" exact="nephritis" post="of HIV-positive patients under atazanavir and tenofovir therapy in"/>
  <result pre="PP. Boceprevir: a protease inhibitor for the treatment of chronic" exact="hepatitis" post="C [Epub ahead of print August 9, 2011]. Ann"/>
  <result pre="treated chronic HCV genotype 1 infectionN Engl J Med36420111207121721449784 197PawlotskyJMChevaliezSMcHutchisonJGThe" exact="hepatitis" post="C virus life cycle as a target for new"/>
  <result pre="life cycle as a target for new antiviral therapiesGastroenterology13220071979199817484890 198SarrazinCKiefferTLBartelsDDynamic" exact="hepatitis" post="C virus genotypic and phenotypic changes in patients treated"/>
  <result pre="HCV infectionN Engl J Med36020091839185019403903 201JacobsonIMMcHutchisonJGDusheikoGTelaprevir for previously untreated chronic" exact="hepatitis" post="C virus infectionN Engl J Med36420112405241621696307 202ZeuzemSAndreonePPolSTelaprevir for retreatment"/>
  <result pre="herpesviruses; (2) discuss options for the prevention and treatment of" exact="influenza" post="virus, including infections with resistant strains; and (3) discuss"/>
  <result pre="and (3) discuss antiviral drugs for the treatment of chronic" exact="hepatitis" post="B and C infections, including novel nucleos(t)ide analogues and"/>
 </snippets>
</snippetsTree>
